跳轉至內容
Merck
全部照片(1)

文件

P0080

Sigma-Aldrich

普伦司特 半水合物

≥98% (HPLC), white, solid

同義詞:

8-[4(4-phenylbutoxy)benzoyl]amino-2-(5-tetrazolyl)-4-oxo-4H-1-benzopyran

登入查看組織和合約定價


About This Item

經驗公式(希爾表示法):
C27H23N5O4 · 0.5 H2O
CAS號碼:
分子量::
490.51
MDL號碼:
分類程式碼代碼:
51111800
PubChem物質ID:
NACRES:
NA.77

化驗

≥98% (HPLC)

形狀

solid

顏色

white

溶解度

DMSO: ≥10 mg/mL
H2O: insoluble

儲存溫度

−20°C

SMILES 字串

O.O=C(Nc1cccc2C(=O)C=C(Oc12)c3nnn[nH]3)c4ccc(OCCCCc5ccccc5)cc4.O=C(Nc6cccc7C(=O)C=C(Oc67)c8nnn[nH]8)c9ccc(OCCCCc%10ccccc%10)cc9

InChI

1S/2C27H23N5O4.H2O/c2*33-23-17-24(26-29-31-32-30-26)36-25-21(23)10-6-11-22(25)28-27(34)19-12-14-20(15-13-19)35-16-5-4-9-18-7-2-1-3-8-18;/h2*1-3,6-8,10-15,17H,4-5,9,16H2,(H,28,34)(H,29,30,31,32);1H2

InChI 密鑰

MSXTUBJFNBZPGC-UHFFFAOYSA-N

生化/生理作用

Pranlukast is a subtype specific CysLT1 receptor antagonist. Leukotrienes are involved in the inflammation response and are divided into two main classes; leukotriene B4 and cysteinyl-substituted leukotrienes.

特點和優勢

This compound is featured on the Leukotriene Receptors page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

象形圖

Exclamation mark

訊號詞

Warning

危險分類

Acute Tox. 4 Oral - Aquatic Chronic 4 - Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3

標靶器官

Respiratory system

儲存類別代碼

11 - Combustible Solids

水污染物質分類(WGK)

WGK 3

閃點(°F)

Not applicable

閃點(°C)

Not applicable

個人防護裝備

dust mask type N95 (US), Eyeshields, Gloves


分析證明 (COA)

輸入產品批次/批號來搜索 分析證明 (COA)。在產品’s標籤上找到批次和批號,寫有 ‘Lot’或‘Batch’.。

已經擁有該產品?

您可以在文件庫中找到最近購買的產品相關文件。

存取文件庫

Inés Velázquez-Quesada et al.
Drug design, development and therapy, 14, 1799-1811 (2020-06-05)
Cancer stem cells (CSCs) drive the initiation, maintenance, and therapy response of breast tumors. CD49f is expressed in breast CSCs and functions in the maintenance of stemness. Thus, blockade of CD49f is a potential therapeutic approach for targeting breast CSCs.
Eun-Sol Ha et al.
Drug design, development and therapy, 9, 3257-3266 (2015-07-08)
The present study was carried out to develop an oral formulation of pranlukast hemihydrate with improved dissolution and oral bioavailability using a surface-modified microparticle. Based on solubility measurements, surface-modified pranlukast hemihydrate microparticles were manufactured using the spray-drying method with hydroxypropylmethyl

我們的科學家團隊在所有研究領域都有豐富的經驗,包括生命科學、材料科學、化學合成、色譜、分析等.

聯絡技術服務